Retained Earnings (Accumulated Deficit) in USD of Ambrx Biopharma, Inc. from Q4 2022 to Q3 2023

Taxonomy & unit: us-gaap: USD
Description: The cumulative amount of the reporting entity's undistributed earnings or deficit.
Summary: Ambrx Biopharma, Inc. quarterly Retained Earnings (Accumulated Deficit) history and change rate from Q4 2022 to Q3 2023.
Ambrx Biopharma, Inc. Retained Earnings (Accumulated Deficit) for the quarter ending 30 Sep 2023 was $347,745,000.
Source SEC data: View on sec.gov

Retained Earnings (Accumulated Deficit), Quarterly (USD)

Ambrx Biopharma, Inc. Quarterly Retained Earnings (Accumulated Deficit) (USD)

Period	Value	YoY Chg	Change %	Date	Report	Filed	Fiscal Year	Fiscal Period
Q3 2023	$347,745,000			30 Sep 2023	10-Q	13 Nov 2023	2023	Q3
Q4 2022	$291,628,000			31 Dec 2022	10-Q	13 Nov 2023	2023	Q3

* An asterisk sign (*) next to the value indicates that the value is likely invalid.